ANI Pharmaceuticals, Inc.ANIPNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank50
3Y CAGR-45.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-45.2%/yr
vs +8.4%/yr prior
Acceleration
-53.6pp
Decelerating
Percentile
P50
Within normal range
vs 3Y Ago
0.2x
Contraction
Streak
3 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 15.89% |
| 2024 | 30.03% |
| 2023 | 53.62% |
| 2022 | 96.31% |
| 2021 | -28.95% |
| 2020 | -19.21% |
| 2019 | 28.71% |
| 2018 | 69.66% |
| 2017 | 212.11% |
| 2016 | 1.11% |